CORRECTION

Correction: S-Nitrosylation of G proteincoupled receptor kinase 6 and Casein kinase 2 alpha modulates their kinase activity toward alpha-synuclein phosphorylation in an animal model of Parkinson's disease

Weiwei Wu, Chun Chau Sung, Peichun Yu, Jiahua Li, Kenny K. K. Chung

In Figs <u>3–7</u>, there are incorrect symbols in the labels. Please view the correct figures here.



## G OPEN ACCESS

**Citation:** Wu W, Sung CC, Yu P, Li J, Chung KKK (2020) Correction: S-Nitrosylation of G proteincoupled receptor kinase 6 and Casein kinase 2 alpha modulates their kinase activity toward alphasynuclein phosphorylation in an animal model of Parkinson's disease. PLoS ONE 15(6): e0235296. https://doi.org/10.1371/journal.pone.0235296

Published: June 18, 2020

**Copyright:** © 2020 Wu et al. This is an open access article distributed under the terms of the <u>Creative</u> Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



**Fig 3. Aging increases GRK6 and CK2α S-nitrosylation in an A53T α-syn transgenic mouse model of PD.** (A) Hemizygous A53T α-syn transgenic mouse brain samples of 6, 9 and 12 months old were analyzed with in vivo biotinswitch assay for GRK6, CK2α and GAPDH. The samples were also subject to Western blot analysis of GRK6, CK2α, GAPDH, pSer129 α-syn and α-syn. (→: GRK6 band) (B) Quantification of hemizygous A53T α-syn transgenic mouse brain samples for in vivo CK2α S-nitrosylation as in (A) (\* p < 0.05, \*\* p < 0.01; # of animals = 3 for each time point; one-way ANOVA with Bonferroni post-hoc test). (C) Quantification of hemizygous A53T α-syn transgenic mouse brain samples for in vivo GRK6 S-nitrosylation as in (A) (\* p < 0.05; # of animals = 3 for each time point; one-way ANOVA with Bonferroni post-hoc test). (D) Quantification of hemizygous A53T α-syn transgenic mouse brain samples for in vivo GRK6 S-nitrosylation as in (A) (\* p < 0.05; # of animals = 3 for each time point; one-way ANOVA with Bonferroni post-hoc test). (D) Quantification of hemizygous A53T α-syn transgenic mouse brain samples for in vivo GRPDH S-nitrosylation as in (A) (\* p < 0.05; # of animals = 3 for each time point; one-way ANOVA with Bonferroni post-hoc test). (E) Quantification of hemizygous A53T α-syn transgenic mouse brain samples for protein levels of pSer129 α-syn as in (A) (# of animals = 3 for each time point). (F) Quantification of hemizygous A53T α-syn transgenic mouse brain samples for protein levels of pSer129 α-syn as in (A) (# of animals = 3 for each time point). (F) Quantification of hemizygous A53T α-syn transgenic mouse brain samples for protein levels of pSer129 α-syn as in (A) (# of animals = 3 for each time point). (F) Quantification of hemizygous A53T α-syn transgenic mouse brain samples for protein levels of pSer129 α-syn as in (A) (# of animals = 3 for each time point). (F) Quantification of hemizygous A53T α-syn transgenic mouse brain samples for protein levels of α-syn as in (A) (# of animals = 3 for each



Fig 4. A53T α-syn transgenic expression increases S-nitrosylation of GRK6, CK2α and GAPDH in the mouse brain. (A) WT, and hemizygous A53T α-syn transgenic mouse brain samples of 9 months old treated with or without L-NNA were analyzed with in vivo biotin-switch assay for CK2α and GAPDH. The samples were also subject to Western blot analysis of CK2α, GAPDH, pSer129 α-syn and α-syn. (→: GRK6 band) (B) Quantification of WT and hemizygous A53T α-syn transgenic mouse brain samples for in vivo CK2α S-nitrosylation as in (A) (\* p < 0.05; no. of animals = 3 in each group; two-way ANOVA with Bonferroni post-hoc test). (C) Quantification of WT and hemizygous A53T α-syn transgenic mouse brain samples for in vivo GRK6 S-nitrosylation as in (A) (\* p < 0.05; # of animals = 3 in each group; two-way ANOVA with Bonferroni post-hoc test). (D) Quantification of WT and hemizygous A53T α-syn transgenic mouse brain samples for in vivo GRH6 S-nitrosylation as in (A) (\* p < 0.05; # of animals = 3 in each group; two-way ANOVA with Bonferroni post-hoc test). (D) Quantification of WT and hemizygous A53T α-syn transgenic mouse brain samples for in vivo GAPDH S-nitrosylation as in (A). (E) Quantification of WT and hemizygous A53T α-syn transgenic mouse brain samples for protein levels of pSer129 α-syn as in (A) (# of animals = 3 in each group). (F) Quantification of WT and hemizygous A53T α-syn transgenic mouse brain samples for protein levels of α-syn as in (A) (# of animals = 3 in each group).



6 months

Fig 5. Deletion of neuronal NOS (nNOS) reduces the accumulation of pSer129  $\alpha$ -syn in 6-month-old A53T  $\alpha$ -syn transgenic mice. (A) Hemizygous A53T  $\alpha$ -syn transgenic mouse brain (A53T -/+), and hemizygous A53T  $\alpha$ -syn transgenic and nNOS heterozygous knockout (A53T -/+; nNOS -/+) double mutant mouse brain samples at 6-month-old were analyzed with in vivo biotin-switch assay for CK2 $\alpha$  and GAPDH. The samples were also subject to Western blot analysis of CK2 $\alpha$ , GAPDH, pSer129  $\alpha$ -syn and  $\alpha$ -syn. ( $\rightarrow$ : GRK6 band) (B) Quantification of CK2 $\alpha$ , GRK6 and GAPDH S-nitrosylation and protein levels of pSer129  $\alpha$ -syn and  $\alpha$ -syn as in (A) (\* p<0.05; # of animals = 3 in each group; Student's t-test).



Fig 6. Deletion of neuronal NOS (nNOS) reduces the accumulation of pSer129  $\alpha$ -syn and total  $\alpha$ -syn in 9-monthold A53T  $\alpha$ -syn transgenic mice. (A) Hemizygous A53T  $\alpha$ -syn transgenic mouse brain (A53T -/+), and hemizygous A53T  $\alpha$ -syn transgenic and nNOS heterozygous knockout (A53T -/+; nNOS -/+) double mutant mouse brain samples at 9-month-old were analyzed with in vivo biotin-switch assay for CK2 $\alpha$  and GAPDH. The samples were also subject to Western blot analysis of CK2 $\alpha$ , GAPDH, pSer129  $\alpha$ -syn and  $\alpha$ -syn. ( $\rightarrow$ : GRK6 band) (B) Quantification of CK2 $\alpha$ , GRK6 and GAPDH S-nitrosylation and protein levels of pSer129  $\alpha$ -syn and  $\alpha$ -syn as in (A) (\*\*\* p<0.001; \*\* P<0.01; # of animals = 3 in each group; Student's t-test).







PLOS ONE | https://doi.org/10.1371/journal.pone.0235296 June 18, 2020

old were analyzed with in vivo biotin-switch assay for CK2 $\alpha$  and GAPDH. The samples were also subject to Western blot analysis of CK2 $\alpha$ , GAPDH, pSer129  $\alpha$ -syn and  $\alpha$ -syn. ( $\rightarrow$ : GRK6 band) (B) Quantification of CK2 $\alpha$ , GRK6 and GAPDH S-nitrosylation and protein levels of pSer129  $\alpha$ -syn and  $\alpha$ -syn as in (A) (\* p<0.05; \*\* p<0.01; # of animals = 4 in each group; Student's t-test).

https://doi.org/10.1371/journal.pone.0235296.g005

## Reference

 Wu W, Sung CC, Yu P, Li J, Chung KKK (2020) S-Nitrosylation of G protein-coupled receptor kinase 6 and Casein kinase 2 alpha modulates their kinase activity toward alpha-synuclein phosphorylation in an animal model of Parkinson's disease. PLoS ONE 15(4): e0232019. https://doi.org/10.1371/journal. pone.0232019 PMID: 32343709